丙戊酸使用与黑色素瘤风险的关联
本研究基于Kaiser Permanente北加州成年白人成员(n=2,213,845)的回顾性队列(1997-2012),发现丙戊酸暴露者黑色素瘤发病率较低(64.0 vs 96.2/100,000人年,P<0.001),调整后风险比HR=0.76(95%CI 0.61-0.94),但累积暴露分析显示生物学上不合理的负剂量效应,提示可能存在残余混杂。
要点
- 丙戊酸暴露与黑色素瘤风险降低相关(调整HR=0.76)。
- 暴露者诊断时更多为局部病变(97.6% vs 92.6%)。
- 累积暴露分析显示负剂量效应,提示残余混杂可能。
核心结论
- 丙戊酸暴露可能与黑色素瘤风险降低及进展减少相关,但累积暴露分析提示观察结果可能源于残余混杂。
研究设计与样本
- 回顾性队列研究,纳入1997至2012年Kaiser Permanente北加州成年白人成员n=2,213,845。
主要发现
- 暴露组黑色素瘤发病率为64.0/100,000人年,非暴露组为96.2/100,000人年(P<0.001)。
- 未调整分析中暴露组黑色素瘤风险较低(HR=0.64;95%CI=0.51-0.79)。
- 调整年龄、性别、日历年及医疗使用后,风险估计减弱但仍显著(HR=0.76;95%CI=0.61-0.94)。
- 基于配药次数的累积暴露分析显示生物学上不合理的负剂量效应。
- 暴露组诊断时局部病变比例更高(97.6% vs 92.6%)。
临床怎么用
- 丙戊酸暴露与黑色素瘤风险降低相关,但累积暴露分析提示残余混杂可能,临床应用需谨慎解读。
局限性
- 累积暴露分析显示生物学上不合理的负剂量效应,提示可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiation and apoptosis in melanoma cells. No published pharmacoepidemiologic studies have explored the association between valproic acid use and melanoma risk. We conducted a retrospective cohort study of adult white Kaiser Permanente Northern California members (n = 2,213,845) from 1997 to 2012 to examine the association between valproic acid use and melanoma risk. Melanoma hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models, adjusted for age, sex, calendar year, and healthcare use. Melanoma incidence was lower among exposed individuals (64.0 exposed vs. 96.2 unexposed per 100,000 person-years, P < 0.001). Exposed individuals had a lower incident melanoma risk (HR = 0.64; 95% CI = 0.51-0.79) in unadjusted analysis, and the estimate was attenuated but significant in adjusted analysis (HR = 0.76, 95% CI = 0.61-0.94). Cumulative exposure based on the number of fills revealed a biologically implausible inverse dose-effect. Exposed individuals were more likely to present with local than regional or distant disease at diagnosis (80/82; 97.6% exposed vs. 12,940/13,971; 92.6% unexposed). Our findings suggest that valproic acid exposure may be associated with decreased melanoma risk and progression, but the cumulative exposure analyses suggest that the observation may be owing to residual confounding.
引用
- Chavez A, Quesenberry CP, Darbinian J, et al. Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk. J Invest Dermatol. 2020. PMID: 32353448. doi:10.1016/j.jid.2020.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。